CTOs on the Move

Cellares

www.cellares.com

 
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.cellares.com
  • 345 Allerton Ave
    South San Francisco, CA USA 94080
  • Phone: 833.235.5273

Executives

Name Title Contact Details

Funding

Cellares raised $18M on 10/29/2020
Cellares raised $832M on 05/05/2021

Similar Companies

Celula Inc

Celula Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Health Services

Meridian Health Services is a progressive healthcare organization specializing in “whole person” health, integrating physical, mental and social well-being. The focus on a broader spectrum of health including primary medical care, behavioral health and human services offers a well-rounded approach for happier, healthier patients. Meridian Health Services has been serving the community for over 35 years and is accredited by the Joint Commission and certified by the Indiana Division of Mental Health and Addictions.

Cellectar

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar's compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of 2014 and results have been submitted to the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

MediGene

MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RootPath Genomics

RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.